Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acumen Pharmaceuticals, Inc. filings document a clinical-stage biopharmaceutical issuer focused on Alzheimer’s disease programs targeting toxic soluble amyloid beta oligomers. Its Form 8-K reports include operating and financial results, business highlights, Regulation FD presentation updates, clinical and nonclinical program disclosures, and material agreements related to Enhanced Brain Delivery development.
Proxy materials describe annual meeting voting matters, board elections, auditor ratification, and equity incentive plan approvals. The filing record also discloses ABOS common stock registered on the Nasdaq Global Select Market, emerging growth company status, governance changes, capital-structure matters, and clinical and regulatory disclosure categories tied to drug development.
Acumen Pharmaceuticals reported that it has furnished an earnings press release and posted an updated investor presentation that reflects the companys cash, cash equivalents and marketable securities balance as of June 30, 2025. The filing states these materials are furnished as Exhibits 99.1 and 99.2 and explicitly notes that the furnished information is not being "filed" under the Exchange Act and is not incorporated by reference in other securities filings.
The Form 8-K does not include numeric financial results within the filing itself; instead it directs readers to the furnished press release and presentation for details. The company also states that the submission is not an admission as to materiality of any Regulation FD disclosures.